Abstract: The present invention provides drug toxicity evaluation platforms (such as an evaluation method and a kit therefor) that enable detailed analysis of the possibility and the like of developing drug-induced damage (such as DILI) to the liver and other organs. The method for evaluating drug toxicity of the present invention includes: a step of adding a drug to a co-culture system of an organoid and blood cells; and a step of evaluating the toxicity of the drug to the organoid.

Abstract: An object of the present invention is to provide a biomarker that enables selection of an embryo having a high rate of implantation and pregnancy, that is, an embryo having high fertility, from embryos obtained through embryo culture after in vitro fertilization in infertility treatment, and a criterion therefor. Provided is a criterion that enables identification of an ovum suitable for implantation and pregnancy based on measurement of the concentration of soluble CD163 which is present in follicular fluid collected at the same time as an ovum in ovum pick up in infertility treatment, or which is present in serum immediately before the ovum pick up.

Abstract: A power supply apparatus includes a power supply configured to apply an alternating current to a magnetic field generation apparatus; and a controller configured to control the alternating current applied by the power supply. The controller controls the power supply to apply the alternating current having a waveform pattern including a plurality of current waveforms having different frequency spectrums from each other.

Abstract: The present invention provides a marker gene capable of detecting the undifferentiated cells that remain or become included in a differentiated cell population. Undifferentiated cells present in a differentiated cell population are detected by using at least one gene selected from the group consisting of LINC00678 and PRDM14 as an undifferentiation marker. A method of detecting undifferentiated cells; a method of using the gene as an undifferentiation marker; and a kit for detecting undifferentiated cells. A method of selecting an undifferentiated cell clone is also provided.

Abstract: An object of the present invention is to provide a SARS-CoV-2 detection kit and a SARS-CoV-2 detection method which make it possible to simply detect SARS-CoV-2 with higher sensitivity. According to the present invention, there is provided a SARS-CoV-2 detection kit which is for specifically detecting a nucleocapsid protein contained in a biological specimen and contains at least one antibody that specifically reacts with a SARS-CoV-2 nucleocapsid protein (NP), the SARS-CoV-2 detection kit including a first container that houses a silver-containing compound, and a second container that houses a reducing agent capable of reducing silver ions, in which the antibody includes at least one antibody that belongs to a subclass IgG2b.

Abstract: An object of the present invention is to provide a composition for preventing or improving fat deposition on the liver in spite of the alcohol intake history of a level that a liver disease is not caused. The inventors found that glutathione has an effect of preventing or improving fat deposition on the liver, which is not caused by alcohol, and completed the present invention. Among nonalcoholic fat diseases, the present invention is particularly effective in an early stage of the treatment or in a case where treatment for another disease is not performed.

Abstract: A power supply apparatus includes a power supply configured to apply an alternating current to a magnetic field generation apparatus; and a controller configured to control the alternating current applied by the power supply. The controller controls the power supply to apply the alternating current having a waveform pattern including a plurality of current waveforms having different frequency spectrums from each other.

Abstract: The present invention provides a sensitive and simple detection method, and a kit therefor, which detects residual undifferentiated human pluripotent stem cells in an intermediate product and/or a final product of a regenerative medical products, using an isothermal nucleic acid amplification method, and specifically, a LAMP method. A method for detecting presence or absence of undifferentiated cells in a non-undifferentiated cell population, wherein RNA derived from an undifferentiation marker gene exhibiting a significant difference in expression level between the undifferentiated cells and the non-undifferentiated cells in a sample containing a nucleic acid derived from the cell population of interest is detected by the isothermal nucleic acid amplification method.

Abstract: An object of the invention is to provide a method for detecting pancreatic cancer and a reagent that can be used for the method. The method is a method for detecting pancreatic cancer, characterized by comprising measuring the amount of TFPI2 in a body fluid collected from a subject. In addition, an antibody that specifically recognizes the TFPI2 processing polypeptide and intact TFPI2 is included in the reagent for detecting pancreatic cancer.

Abstract: Disclosed are a means which enables simple and rapid detection of the presence or absence, and of the degree, of homologous recombination activity in an individual, and a means which is useful for detection and treatment of homologous recombination-restored cancer for which no treatment means is available at present. The nucleic acid construct of the present invention comprises: (1) a promoter region; (2) a mutant gene sequence containing a cleavage site in a gene sequence encoding a protein; and (3) a base sequence composed of a first homologous region and a second homologous region, the base sequence being capable of replacing, by homologous recombination, a partial region in the mutant gene sequence of (2), the partial region containing the cleavage site.

Abstract: An object of the present invention is to provide a method for detecting malignant ovarian tumor as distinguished from benign ovarian tumor, and a reagent that can be used for the method. Provided are a method for detecting malignant ovarian tumor (excluding high-grade serous carcinoma) as distinguished from benign ovarian tumor, characterized by measuring the amount of TFPI2 in a sample from a patient, and a reagent for detecting malignant ovarian tumor (excluding high-grade serous carcinoma) as distinguished from benign ovarian tumor contains an antibody that specifically recognizes TFPI2 processing polypeptide and intact TFPI2.

Abstract: Disclosed is means which enables simple and rapid detection of the presence or absence of mismatch repair activity, and which is useful for diagnosis and treatment of mismatch repair-deficient cancers. In an integrated-type nucleic acid construct provided by the present invention, [promoter region], [5?-side region+first homologous region], and [second homologous region+3?-side region] are placed in the same nucleic acid molecule. In a divided-type nucleic acid construct, [promoter region], [5?-side region+first homologous region], and [second homologous region+3?-side region] are placed in two different nucleic acid molecules. The nucleic acid construct of the present invention can be used as a therapeutic agent for mismatch repair-deficient cancer, as a diagnostic agent for mismatch repair-deficient cancer, or as a companion diagnostic agent for predicting an effect of an anticancer drug for mismatch repair-deficient cancer, containing the nucleic acid construct.

Abstract: The present invention provides a method of constituting a tissue construct in vitro using a tissue without depending on scaffold materials. A method of integrating a biological tissue with a vascular system in vitro, comprising coculturing a biological tissue with vascular cells and mesenchymal cells. A biological tissue which has been integrated with a vascular system by the above-described method. A method of preparing a tissue or an organ, comprising transplanting the biological tissue described above into a non-human animal and differentiating the biological tissue into a tissue or an organ in which vascular networks have been constructed. A method of regeneration or function recovery of a tissue or an organ, comprising transplanting the biological tissue described above into a human or a non-human animal and differentiating the biological tissue into a tissue or an organ in which vascular networks have been constructed.

Abstract: The present invention aims to provide a method for simply and highly accurately detecting castration-resistant prostate cancer (CRPC), and a reagent that can be used for this method. By measuring the level of GDF15 propeptide present in a sample as a novel detection marker for CRPC, acquisition of castration resistance in a prostate cancer patient during or after endocrine therapy is detected. An antibody that specifically recognizes GDF15 propeptide is included in the CRPC detection reagent.

Abstract: The disclosure provides a method for producing hepatocytes or hepatic progenitor cells; a method for suppressing hepatocyte aging using a drug causing histone hyperacetylation; a hepatocyte anti-aging agent; a method for increasing hepatocyte plasticity; and a drug for increasing hepatocyte plasticity.

Abstract: Disclosed is a novel means for accurate qualitative and quantitative analyses for each N-glycosylation site. The method of analyzing N-linked sugar chain(s) of glycoprotein according to the present invention comprises: treating a part of a glycopeptide-containing sample to be analyzed with endo-?-N-acetylglucosaminidases to cleave off sugar chains while leaving one GlcNAc of the chitobiose core on the Asn at the N-glycosylation site; subjecting the obtained sugar chain-cleaved sample to preliminary liquid chromatography/mass spectrometry; predicting the retention time of the glycopeptide of interest and the mass-to-charge ratio (m/z) of the precursor ion in main analysis based on the results of the preliminary liquid chromatography/mass spectrometry; and carrying out the main analysis. By this method, the binding sites and structures of N-linked sugar chains in a glycoprotein can be analyzed.

Abstract: Provided are anti-PAD4 antibodies having excellent properties and an excellent method for treatment of RA. Used are anti-PAD4 antibodies that specifically bind to an epitope containing positions 345, 347, and 348 of PAD4. These anti-PAD4 antibodies may inhibit the citrullination activity of PAD4. In addition, these anti-PAD4 antibodies may have a KD (M) of 9.0×10?9 or less. Optionally, the anti-PAD4 antibody and a TNF? inhibitor are used in combination.

Abstract: The present invention relates to a method for distinguishing a first nucleic acid sequence from a second nucleic acid sequence by electrophoresis. The first nucleic acid comprises a first common sequence tract, a variable sequence tract and a second common sequence tract and the second nucleic acid comprises a first common sequence tract, optionally an variable sequence tract and a second common sequence tract. The first and the second nucleic acid sequence is contacted with a probe sequence that is reverse complementary to the first and second common sequence tract under conditions allowing the hybridization of the probe sequence to the first and second nucleic acid sequence, thereby forming a first probe hybrid and a second probe hybrid. Subsequently, the first and second probe hybrids are submitted to electrophoresis to detect the electrophoretic mobility of the first and second probe hybrid.

Abstract: A method for screening for a therapeutic drug for a disease involving excessive activation of a complement, using a s cytotoxicity marker associated with the complement as an index, including (1a) a step of adding a complement to a cell produced from a stem cell to cause the cell to form a cytotoxicity marker associated with the complement, and (2a) a step of adding a therapeutic drug candidate, and selecting a substance that decreases the amount of the cytotoxicity marker is provided by the present invention.

Abstract: A cancer treatment apparatus including a magnetic field generator that generates a magnetic field of 100 kHz to 300 kHz to be applied to affected tissues.